GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (NAS:XTLB) » Definitions » GF Value Rank

XTL Biopharmaceuticals (XTL Biopharmaceuticals) GF Value Rank : 0 (As of May. 06, 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals GF Value Rank?

XTL Biopharmaceuticals has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

XTL Biopharmaceuticals GF Value Rank Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

XTL Biopharmaceuticals (XTL Biopharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (NAS:XTLB) » Definitions » GF Value Rank
Comparable Companies
XTAE:PPBT XTAE:CANF XTAE:MTLF XTAE:CBI XTAE:KDST XTAE:BOLT XTAE:PLNT XTAE:HDST-M XTAE:DNA XTAE:GFC-M OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
XTLB:Israel H2K2:Germany
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
Website
https://www.xtlbio.com
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Executives
Kenneth J Zuerblis director 20 KINGSBRIDGE RD, PISCATAWAY NJ 08854
Jennifer L Good director 15 GREAT RING ROAD, SANDY HOOK CT 06482
Samuel Rudman director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ben-zion Weiner director 3 HAYOGEV STREET, MOSHAV MAZOR L3 73160
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Michael Cho 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott Bradley 10 percent owner PERCEPTIVE ADVISORS LLC, 499 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
William Kessler officer: Director of Finance C/O XTL BIOPHARMACEUTICALS LTD., 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989
Ron Bentsur officer: CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
William James Kennedy director C/O XTL BIOPHARMACEUTICALS LTD, 711 EXECUTIVE BLVD., SUITE Q, VALLEY COTTAGE NY 10989